January 2023 News & Announcements

August 2023

Dr. Caitlin Gerdts receives Society of Family Planning’s 2023 lifetime achievement award

August 22, 2023 – Today, the Society of Family Planning announced that Ibis’s Vice President for Research, Dr. Caitlin Gerdts , has received their 2023 Lifetime Achievement Award , which honors individuals who have dedicated their careers to advancing the science of abortion and...
July 2023

FDA approves the first-ever over-the-counter birth control pill in the United States

July 13, 2023 - Today, in a historic move for reproductive health that could transform contraception access, the United States Food and Drug Administration (FDA) approved Opill, a progestin-only birth control pill (POP), for over-the-counter (OTC) use. After a comprehensive review of the data and a...
June 2023

Ibis attends the 2023 South Africa AIDS Conference

June 2023

One year after Dobbs, Ibis remains committed to expanding abortion access

Cambridge, MA, June 23, 2023 – On June 24, 2022, The US Supreme Court released a final decision on Dobbs v. Jackson Women’s Health Organization , which eliminated constitutional protections of the right to abortion care established by Roe v. Wade in 1973. While the protections granted...
June 2023

Biden issues executive order on improving access to contraception

June 26, 2023 – Last Friday, the Biden Administration issued an executive order on “Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services” . The executive order includes an explicit directive to the Secretaries of the Treasury, Labor and HHS...
May 2023

Regina Tamés and Jay Zussman join Ibis Board of Directors; Fatimah Gifford starts term as Board Chair

We are thrilled to announce that Regina Tamés and Jay Zussman have joined the Ibis Board of Directors as Members at Large, and Fatimah Gifford is starting her term as Board Chair. Fatimah will be building on the work of former Board Chair Thoai Ngo to continue to advance racial justice and...
May 2023

FDA advisory committee votes unanimously to recommend Opill for over-the-counter use

May 10, 2023 – Today, in a landmark step for reproductive health, a joint FDA advisory committee voted unanimously to allow a birth control pill to be offered over the counter (OTC). The advisory committee vote reflects the decades of science showing that birth control pills are safe and...
April 2023

Ibis responds to federal court decisions on mifepristone registration and availability

Cambridge, MA, April 10, 2023 – On Friday, April 7, 2023, a judge in a Texas federal court released a ruling in Alliance for Hippocratic Medicine v. FDA. The ruling places a stay on the FDA’s approval of mifepristone and seeks to remove it from the market nationwide. The same day...
March 2023

FDA schedules advisory committee meeting for over-the-counter birth control pill to take place May 9-10

The FDA announced today that an advisory committee meeting is scheduled for May 9 and 10 to review the first-ever application for an over-the-counter birth control pill. In July 2022, HRA Pharma announced it had submitted this application to the FDA to switch Opill, a progestin-only, daily birth...
March 2023

Exciting new partnership will advance comprehensive sexuality education in sub-Saharan Africa

Ibis Reproductive Health South Africa is proud to announce its partnership with Advocates For Youth (AFY) as the new Sub-Saharan Africa regional lead for the AMAZE Africa initiative, with the intention of amplifying ongoing efforts in the region to make comprehensive sexuality education resources...
March 2023

AMAZE Africa media event amplified sexuality education in Sub-Saharan Africa

Insights from the World Population Review indicate that over 13 million children are born to women who are under 20 years old. Disturbingly, more than 90% of these births (about 12 million) occur in developing countries, with African countries topping the list. To address high rates of teenage...